105P - Risk factors associated with symptomatic radiation pneumonitis after stereotactic body radiation therapy for stage I non-small cell lung cancer

Date 15 April 2016
Event European Lung Cancer Conference 2016 (ELCC) 2016
Session Poster lunch
Topics Complications of Treatment
Non-Small-Cell Lung Cancer, Early Stage
Surgery and/or Radiotherapy of Cancer
Presenter Jian He
Citation Journal of Thoracic Oncology (2016) 11 (supplement 4): S57-S166. S1556-0864(16)X0004-4
Authors J. He, Z. Zeng, S. Shi
  • Department Of Radiation Oncology, Zhongshan Hospital, Fudan University, 200032 - Shanghai/CN

Abstract

Background

Radiation pneumonitis (RP) is the most frequent acute pulmonary toxicity following stereotactic body radiation therapy (SBRT) for lung cancer. Here we investigate clinical and dosimetric factors associated with symptomatic RP in stage I non-small cell lung cancer (NSCLC) patients treated with SBRT.

Methods

A total of 67 patients with stage I NSCLC who received SBRT at our institution were enrolled and their clinicopathological parameters and dosimetric parameters were recorded and analyzed.

Results

The median follow-up period was 26.4 months (range, 7–48 months). In univariable analysis, tumor size (P = 0.041), mean lung dose (MLD; P = 0.028), V2.5 (P = 0.024), V5 (P = 0.014), V10 (P = 0.004), V20 (P = 0.024), V30 (P = 0.020), V40 (P = 0.040), V50 (P = 0.040) were associated with symptomatic RP. In multivariable logistic regression analysis, V10 (P = 0.049) was significantly associated with symptomatic RP.

Conclusions

In conclusion, this study found that tumor size, MLD and V2.5–50 were risk factors markedly associated with symptomatic RP.V10 was the most significant factor and planning constraints should be optimized to minimize the lung dose V10.For both central and peripheral stage I lung cancer, rates of RP ≥ grade 2 was low after SBRT with appropriate fraction dose and it has no correlation with the location of radiation field.

Clinical trial identification

ChiCTR-OPN-15006864 (Chinese Clinical Trial Registry)

Legal entity responsible for the study

N/A

Funding

N/A

Disclosure

All authors have declared no conflicts of interest.